Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
IMCR similar filings
- 3 Jun 22 Sanofi will evaluate KIMMTRAK in combination with SAR444245 as part of its ongoing Phase 1 study in advanced unresectable or metastatic skin cancers
- 12 May 22 Current report (foreign)
- 11 May 22 Index to Unaudited Condensed Consolidated Interim Financial Statements
- 14 Apr 22 Current report (foreign)
- 4 Apr 22 European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
- 3 Mar 22 Immunocore Reports Full Year 2021 Financial Results
- 26 Jan 22 Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
Filing view
External links